Overview
The goal of this study was to identify and understand genetic factors that contribute to Sjögren’s disease. Our team used powerful, cutting-edge technologies to gain new insight into a variety of autoimmune diseases. The study was completed with the Accelerating Medicines Partnership, which is a collaboration between the government (NIH), private industry, and the Sjögren’s Foundation.
Key Facts
- Status: Completed
- Dates: January 2023 – December 2025
- Principal Investigator: Alan N. Baer, MD
- Location: our branch of the study was conducted at multiple Johns Hopkins Medicine locations in Baltimore, MD
Study Design
The study looked at individuals who were either diagnosed with Sjögren’s disease or had clinical symptoms which were strongly suggestive of it. It included many individuals who participated in the Sjögren’s International Collaborative Clinical Alliance (SICCA) study, or in the OMRF Sjögren’s study between 2004 and 2012.
Study participants completed a health history questionnaire and underwent a half-day clinical evaluation to assess the extent of oral, ocular, and rheumatological manifestations of Sjögren’s disease. This included the measurement of saliva output and the collection of saliva, tears and blood. Additionally, a biopsy of the lower lip was performed to collect minor salivary glands, which are used to accurately assess for chronic inflammation of the salivary glands.
Impact
This research has provided valuable knowledge about Sjögren’s disease that is likely to facilitate the development of better treatments.
